Duncan Peyton
Founder chez 4D PHARMA PLC
Profil
Duncan Peyton founded 4D Pharma Plc and Aquarius Equity Partners Ltd.
Presently, Mr. Peyton is CEO, Secretary & Executive Director at 4D Pharma Plc and Director at Aquarius Equity Partners Ltd.
In his past career he occupied the position of Investment Manager at 3i Plc.
Mr. Peyton received an undergraduate degree from the University of Sunderland.
Postes actifs de Duncan Peyton
Sociétés | Poste | Début |
---|---|---|
4D PHARMA PLC | Founder | 18/01/2014 |
Aquarius Equity Partners Ltd.
Aquarius Equity Partners Ltd. Investment ManagersFinance Aquarius Equity Partners Ltd is an independent private equity firm founded in the year 2002 by Alan John Aubrey and Duncan Joseph Peyton headquarters in the UK. | Founder | 01/01/2005 |
Anciens postes connus de Duncan Peyton
Sociétés | Poste | Fin |
---|---|---|
HVIVO PLC | Director/Board Member | 21/05/2014 |
3i Plc
3i Plc Financial ConglomeratesFinance 3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom. | Chief Investment Officer | - |
GT Biologics Ltd.
GT Biologics Ltd. Pharmaceuticals: MajorHealth Technology GT Biologics Ltd. manufactures and distributes pharmaceutical products. It develops and commercializes an oral-based probiotic product for the treatment of mild to moderate Crohn's disease and ulcerative colitis and a novel family of protein, peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases. The company was founded by Denise Kelly in 2008 and is headquartered in Leeds, the United Kingdom. | Director/Board Member | - |
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Director/Board Member | - |
Formation de Duncan Peyton
University of Sunderland | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
4D PHARMA PLC | Health Technology |
Entreprise privées | 5 |
---|---|
hVIVO Ltd.
hVIVO Ltd. Miscellaneous Commercial ServicesCommercial Services hVIVO Ltd. engages in the provision of clinical development services with a focus on human disease models. It specializes in human challenge studies using influenza, human rhinovirus, and respiratory syncytial virus for pharmaceutical and biotech companies. The company was founded by John Sidney Oxford in 1989 and is headquartered in London, the United Kingdom. | Commercial Services |
3i Plc
3i Plc Financial ConglomeratesFinance 3i Plc operates as an private equity firm and provides investment advice. The company was founded on July 21, 1945 and is headquartered in London, the United Kingdom. | Finance |
Aquarius Equity Partners Ltd.
Aquarius Equity Partners Ltd. Investment ManagersFinance Aquarius Equity Partners Ltd is an independent private equity firm founded in the year 2002 by Alan John Aubrey and Duncan Joseph Peyton headquarters in the UK. | Finance |
GT Biologics Ltd.
GT Biologics Ltd. Pharmaceuticals: MajorHealth Technology GT Biologics Ltd. manufactures and distributes pharmaceutical products. It develops and commercializes an oral-based probiotic product for the treatment of mild to moderate Crohn's disease and ulcerative colitis and a novel family of protein, peptide therapeutics for the treatment of moderate to severe inflammatory bowel diseases. The company was founded by Denise Kelly in 2008 and is headquartered in Leeds, the United Kingdom. | Health Technology |
C4X Discovery Ltd.
C4X Discovery Ltd. Pharmaceuticals: MajorHealth Technology C4X Discovery Ltd. engages in the discovery and development of medical drugs. It uses its NMR-based technology to solve the dynamic 3D structures of a broad range of biomolecules, including peptides, cofactors, oligonucleotides and carbohydrates. The company was founded by Andrew Almond and Charles Douglas Blundell in January 2008 and is headquartered in Manchester, the United Kingdom. | Health Technology |